Tissue microarray

Canadian Pathology Quality Assurance Leverages Diaceutics’ DXRX Platform to Advance NTRK IHC Proficiency Testing

Retrieved on: 
Monday, January 18, 2021
Health, Managed care, Research, Pharmaceutical, Science, Biotechnology, Tyrosine kinase receptors, Biology, Microarrays, Trk receptor, Neurotrophic factors, Tissue microarray, Pathology, Life sciences, Diaceutics, CPQA-AQCP

Diaceutics PLC , (AIM: DXRX), today announces a strategic partnership with Canadian Pathology Quality Assurance (CPQA) to advance the development of Neurotrophic Tropomyosin Receptor Kinase (NTRK) IHC proficiency testing globally.

Key Points: 
  • Diaceutics PLC , (AIM: DXRX), today announces a strategic partnership with Canadian Pathology Quality Assurance (CPQA) to advance the development of Neurotrophic Tropomyosin Receptor Kinase (NTRK) IHC proficiency testing globally.
  • Globally, more labs are now testing for NTRK which means there is a growing demand for a robust Proficiency Testing (PT) program in this area.
  • CPQA has identified the need to source Formalin-Fixed Paraffin-Embedded (FFPE) tissue blocks from laboratories to enable them to build a small tissue microarray for the purposes of NTRK IHC proficiency testing and the development of NTRK IHC validation assistance.
  • John Garratt, Director, CPQA said: We are looking forward to taking advantage of Diaceutics extensive network facilitated through DXRX.

Digital Pathology Market Report 2020: Global Industry Size & Share, Trends, Opportunities, Major Companies

Retrieved on: 
Wednesday, February 26, 2020
Biology, Life sciences, Digital pathology, Microscopy, Pathology, Applied Spectral Imaging, Biotechnology, Tissue microarray

The global digital pathology market size is expected to reach USD 1.86 billion by 2027, registering a CAGR of 11.8% over the forecast period.

Key Points: 
  • The global digital pathology market size is expected to reach USD 1.86 billion by 2027, registering a CAGR of 11.8% over the forecast period.
  • Increasing prevalence of chronic diseases triggers the demand for advanced diagnostics, which is expected to drive the market growth.
  • Technological advancements, such as digital imaging, computerization, robotic light microscopy, and multiple fiberoptic communications are some of the key factors driving the adoption of digital pathology.
  • Digital pathology has important role in companion diagnostics and drug development pipeline, including molecular biology, biobanking, molecular tissue profiling, and tissue microarray analysis.